Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717798 | 0.89 | CHRM5 (0.44) | CHRM5ADRA2CACHE | |
| SCHEMBL24723806 | 0.88 | CHRM5 (0.57) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL22783243 | 0.86 | CHRM5 (0.48) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL11596303 | 0.84 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL5376134 | 0.84 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL13606801 | 0.83 | CYP1A2 (0.50) | CHRM5ADRA2CACHEALDH1A1GAA | |
| SCHEMBL25445971 | 0.83 | NCF1 (0.45) | CHRM5ADRA2CACHE | |
| SCHEMBL10241640 | 0.83 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL1777579 | 0.83 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL22297407 | 0.82 | CHRM5 (0.45) | CHRM5ADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | CHRM5 3347/4885ADRA2C 1982/4885ACHE 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.